English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 62805/95882 (66%)
造訪人次 : 3972089      線上人數 : 378
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/115978

    題名: Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
    作者: Chieh-Hsin Lin;Ching-Hua Lin;Yue-Cune Chang;Yu-Jhen Huang;Po-Wei Chen;Hsien-Yuan Lane
    關鍵詞: Antioxidant;Clinical trial;D-amino acid oxidase (DAAO) inhibitor, N-methyl-D-aspartate;Refractory schizophrenia;Sodium benzoate
    日期: 2018-09-15
    上傳時間: 2019-03-14 12:11:03 (UTC+8)
    摘要: BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no
    convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including
    inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for
    patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a
    D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine.
    METHODS: We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that
    had been stabilized with clozapine were allocated into three groups for 6 weeks’ add-on treatment of 1 g/day sodium
    benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative
    Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and
    Global Assessment of Functioning. Side effects and cognitive functions were also measured.
    RESULTS: Both doses of sodium benzoate produced better improvement than placebo in the Scale for the
    Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo
    in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without
    evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated
    with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group.
    CONCLUSIONS: Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant
    schizophrenia. Further studies are warranted to elucidate the optimal
    關聯: Biological Psychiatry 84(6), p.422-432
    DOI: 10.1016/j.biopsych.2017.12.006
    顯示於類別:[數學學系暨研究所] 期刊論文


    檔案 描述 大小格式瀏覽次數



    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋